257 related articles for article (PubMed ID: 30689554)
1. RASSF1A and SOCS1 genes methylation status as a noninvasive marker for hepatocellular carcinoma.
Pasha HF; Mohamed RH; Radwan MI
Cancer Biomark; 2019; 24(2):241-247. PubMed ID: 30689554
[TBL] [Abstract][Full Text] [Related]
2. DNA methylation markers and serum α-fetoprotein level are prognostic factors in hepatocellular carcinoma.
Lin JC; Wu YC; Wu CC; Shih PY; Wang WY; Chien YC
Ann Hepatol; 2015; 14(4):494-504. PubMed ID: 26019036
[TBL] [Abstract][Full Text] [Related]
3. Combination of serum RASSF1A methylation and AFP is a promising non-invasive biomarker for HCC patient with chronic HBV infection.
Dong X; He H; Zhang W; Yu D; Wang X; Chen Y
Diagn Pathol; 2015 Aug; 10():133. PubMed ID: 26238200
[TBL] [Abstract][Full Text] [Related]
4. Quantitative analysis of multiple methylated genes in plasma for the diagnosis and prognosis of hepatocellular carcinoma.
Huang ZH; Hu Y; Hua D; Wu YY; Song MX; Cheng ZH
Exp Mol Pathol; 2011 Dec; 91(3):702-7. PubMed ID: 21884695
[TBL] [Abstract][Full Text] [Related]
5. Methylation of tumour suppressor genes
El-Bendary M; Nour D; Arafa M; Neamatallah M
Br J Biomed Sci; 2020 Jan; 77(1):35-40. PubMed ID: 31790342
[No Abstract] [Full Text] [Related]
6. Quantitative analysis of circulating methylated DNA as a biomarker for hepatocellular carcinoma.
Chan KC; Lai PB; Mok TS; Chan HL; Ding C; Yeung SW; Lo YM
Clin Chem; 2008 Sep; 54(9):1528-36. PubMed ID: 18653827
[TBL] [Abstract][Full Text] [Related]
7. [Aberrant methylation of multiple genes and its clinical implication in hepatocellular carcinoma].
Lou C; Yang B; Gao YT; Wang YJ; Nie FH; Yuan Q; Zhang CL; Du Z
Zhonghua Zhong Liu Za Zhi; 2008 Nov; 30(11):831-6. PubMed ID: 19173828
[TBL] [Abstract][Full Text] [Related]
8. The utility of Lens culinaris agglutinin-reactive alpha-fetoprotein in the diagnosis of hepatocellular carcinoma: evaluation in a United States referral population.
Leerapun A; Suravarapu SV; Bida JP; Clark RJ; Sanders EL; Mettler TA; Stadheim LM; Aderca I; Moser CD; Nagorney DM; LaRusso NF; de Groen PC; Menon KV; Lazaridis KN; Gores GJ; Charlton MR; Roberts RO; Therneau TM; Katzmann JA; Roberts LR
Clin Gastroenterol Hepatol; 2007 Mar; 5(3):394-402; quiz 267. PubMed ID: 17368240
[TBL] [Abstract][Full Text] [Related]
9. TEMs but not DKK1 could serve as complementary biomarkers for AFP in diagnosing AFP-negative hepatocellular carcinoma.
Mao L; Wang Y; Wang D; Han G; Fu S; Wang J
PLoS One; 2017; 12(9):e0183880. PubMed ID: 28902891
[TBL] [Abstract][Full Text] [Related]
10. Combination of LINE-1 hypomethylation and RASSF1A promoter hypermethylation in serum DNA is a non-invasion prognostic biomarker for early recurrence of hepatocellular carcinoma after curative resection.
Liu ZJ; Huang Y; Wei L; He JY; Liu QY; Yu XQ; Li ZL; Zhang J; Li B; Sun CJ; Liang WB; Sun AM; Qin Y
Neoplasma; 2017; 64(5):795-802. PubMed ID: 28592132
[TBL] [Abstract][Full Text] [Related]
11. Diagnostic Value of the Methylation of Multiple Gene Promoters in Serum in Hepatitis B Virus-Related Hepatocellular Carcinoma.
Dong X; Hou Q; Chen Y; Wang X
Dis Markers; 2017; 2017():2929381. PubMed ID: 28951629
[TBL] [Abstract][Full Text] [Related]
12. [A preliminary study of serum marker alpha-enolase in the diagnosis of hepatocellular carcinoma].
Luo X; Wei YQ; Hai L; Hu YC; Zhao ZJ; Ma WL; Ma LN; Liu XY; Ding XC
Zhonghua Gan Zang Bing Za Zhi; 2019 Jul; 27(7):505-510. PubMed ID: 31357775
[No Abstract] [Full Text] [Related]
13. Methylated cysteine dioxygenase-1 gene promoter in the serum is a potential biomarker for hepatitis B virus-related hepatocellular carcinoma.
Yang Y; Fan YC; Gao S; Dou CY; Zhang JJ; Sun FK; Wang K
Tohoku J Exp Med; 2014 Mar; 232(3):187-94. PubMed ID: 24646840
[TBL] [Abstract][Full Text] [Related]
14. Hepatocellular carcinoma suppressor 1 promoter hypermethylation in serum. A diagnostic and prognostic study in hepatitis B.
Tian MM; Fan YC; Zhao J; Gao S; Zhao ZH; Chen LY; Wang K
Clin Res Hepatol Gastroenterol; 2017 Mar; 41(2):171-180. PubMed ID: 28189396
[TBL] [Abstract][Full Text] [Related]
15. Association of RASSF1A hypermethylation with risk of HBV/HCV-induced hepatocellular carcinoma: A meta-analysis.
Peng JL; Wu JZ; Li GJ; Wu JL; Xi YM; Li XQ; Wang L
Pathol Res Pract; 2020 Oct; 216(10):153099. PubMed ID: 32853942
[TBL] [Abstract][Full Text] [Related]
16. Association of serum level of growth differentiation factor 15 with liver cirrhosis and hepatocellular carcinoma.
Liu X; Chi X; Gong Q; Gao L; Niu Y; Chi X; Cheng M; Si Y; Wang M; Zhong J; Niu J; Yang W
PLoS One; 2015; 10(5):e0127518. PubMed ID: 25996938
[TBL] [Abstract][Full Text] [Related]
17. Quantitative analysis of RASSF1A promoter methylation in hepatocellular carcinoma and its prognostic implications.
Xu B; Di J; Wang Z; Han X; Li Z; Luo X; Zheng Q
Biochem Biophys Res Commun; 2013 Aug; 438(2):324-8. PubMed ID: 23891693
[TBL] [Abstract][Full Text] [Related]
18. Hepatocellular Carcinoma Screening Utilising Serum Alpha-Fetoprotein Measurement and Abdominal Ultrasound Is More Effective than Ultrasound Alone in Patients with Non-viral Cirrhosis.
Worland T; Harrison B; Delmenico L; Dowling D
J Gastrointest Cancer; 2018 Dec; 49(4):476-480. PubMed ID: 28920172
[TBL] [Abstract][Full Text] [Related]
19. Cell-free methylation markers with diagnostic and prognostic potential in hepatocellular carcinoma.
Lu CY; Chen SY; Peng HL; Kan PY; Chang WC; Yen CJ
Oncotarget; 2017 Jan; 8(4):6406-6418. PubMed ID: 28031532
[TBL] [Abstract][Full Text] [Related]
20. CpG island methylator phenotype association with elevated serum alpha-fetoprotein level in hepatocellular carcinoma.
Zhang C; Li Z; Cheng Y; Jia F; Li R; Wu M; Li K; Wei L
Clin Cancer Res; 2007 Feb; 13(3):944-52. PubMed ID: 17289889
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]